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See Article, pages 380-387Hepatocellular carcinoma (HCC) is one of the most frequent and
lethal tumours worldwide, accounting for more than 600,000
deaths annually [1,2]. Curative options for HCC are limited to sur-
gical resection and liver transplantation, which can be applied
only to a small subset of patients due to the late diagnosis of
the disease [1,2]. Treatments for unresectable HCC remain
instead unsatisfactory and of marginal beneﬁt for HCC patients
[3]. The only FDA approved drug for HCC is sorafenib, a multikin-
ase inhibitor, whose beneﬁcial effects in terms of survival exten-
sion are rather limited in HCC patients [4]. These disappointing
effects are presumably the consequences of the compensatory
activation of alternative signalling cascades and/or the fact that
sorafenib does not target the underlying mechanisms of hepato-
carcinogenesis in these patients [4]. Thus, a deeper knowledge of
the molecular pathogenesis of HCC is required for the develop-
ment of new and more effective therapeutic strategies against
this deadly disease.
Despite the heterogeneous nature of human HCC, some crucial
signalling pathways involved in hepatocarcinogenesis have been
discovered. Among them, the evolutionary conserved Wnt/b-
catenin cascade has emerged as a pivotal player in liver malig-
nant transformation and tumour progression [5,6]. At the core
of the latter pathway is the b-catenin (CTNNB1) gene, a compo-
nent of submembranous plaques of both adherens junctions
and desmosomes in mammalian cells. Physiologically, b-catenin
is involved in two main functions: intercellular adhesion by
association with E-cadherin, and transmission of the proliferative
signal of the Wnt pathway [7,8]. In the absence of Wnt activation,
the b-catenin protein is rapidly phosphorylated at its NH2-
terminus by the destruction complex, consisting of AXIN1, APC
(adenomatous polyposis coli), GSK-3b (glycogen synthase
kinase-3b), and CK1 (casein kinase 1) proteins [7,8]. Once phos-
phorylated, b-catenin is promptly primed for proteolysis through
the ubiquitin/proteasome system. Mutations in members of the
destruction complex or alternative mechanisms avoiding b-catenin
phosphorylation lead to elevated free pools of b-catenin inJournal of Hepatology 20
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Open access under CC BY-NC-ND license.the cytoplasm, which consequently leads to translocation into
the nucleus and interaction with transcription factors of the
TCF/lymphoid enhancer factor family [7,8]. The newly formed
b-catenin/TCF complex triggers the activation of a number of tar-
get genes involved in cell proliferation, survival, and migration in
a tissue-speciﬁc manner [9]. A body of evidence, coming from
rodent models and human HCC specimens, indicates an impor-
tant role of the Wnt/b-catenin pathway in liver cancer. For
instance, transgenic mouse models overexpressing either a stable
mutant form of b-catenin or a constitutively activated, non-
mutated form of b-catenin show signs of hepatomegaly, although
they do not develop HCC [10,11]. Also, hepatic ablation of APC in
mice leads to HCC development through activation of b-catenin
signalling [12]. In addition, overexpression of mutant b-catenin
cooperates with activated Ha-Ras and AKT1 or with the inacti-
vated Sprouty homolog 2 (SPRY2) protein to induce liver tumour
development in mice [13]. In human HCC, the Wnt/b-catenin cas-
cade is activated in a relatively large subset of tumours, ranging
from 15% to 45%, via either mutations in the b-catenin gene or
alternative molecular mechanisms [5,14]. Taken together, these
ﬁndings indicate that b-catenin might represent an attractive
target in human liver cancer.
To further substantiate the importance of b-catenin inhibition
as a therapeutic modality for human HCC, Delgado et al. have
determined the effect of suppressing mutant b-catenin in vivo
[15]. For this purpose, the authors used a mouse model of liver
cancer, driven by diethylnitrosamine and phenobarbital (DEN/
PB) administration and characterized by the development of liver
tumours with a high rate (90%) of b-catenin mutations [16]. In
this model, b-catenin locked nucleic acid (LNA) antisense treat-
ment was employed, starting 7 months after initiation of the PB
diet, when liver tumours are already present in DEN/PB-initiated
mice. LNA oligonucleotides were injected every 48 h intraperito-
neally at the dose of 15 mg/kg for 10 times [15]. Of note,while sev-
eral glutamine synthase (a b-catenin speciﬁc target gene in the
liver) positive tumour nodules were observed in the livers of
DEN/PB mice, either untreated or treated with a scrambled con-
trol, administration of LNA, targeted against b-catenin, resulted
in the disappearance of microscopic liver tumour nodules in mice,
thus demonstrating a striking therapeutic effect of b-catenin sup-
pression in this model [15]. The complete response to LNA treat-
ment was further underscored in these mice by the serum15 vol. 62 j 257–259
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decrease of leukocyte cell-derived chemotaxin 2 (LECT2), a vali-
date biomarker of b-catenin signalling in mice [17]. At the cellular
level, regression of b-catenin-positive tumourswas paralleled by a
decrease in cell proliferation and apoptosis induction ofmalignant
hepatocytes. Subsequently, the authors investigated whether
b-catenin inhibition could affect tumour growth in the DENmouse
HCC model [16], in which hepatocarcinogenesis is driven by
Ha-Ras or B-Raf mutations and b-catenin is not activated.
Strikingly, LNA directed against b-catenin did not affect tumour
occurrence in this mouse model, implying the therapeutic
efﬁcacy of b-catenin suppression only in liver tumours with active
b-catenin signalling (Fig. 1).
In summary, the intriguing study by Delgado et al. shows for
the ﬁrst time that b-catenin is a druggable target in an in vivo
mouse model of liver cancer. This observation has seminal impli-
cations for the therapy of human HCC. On the one hand, it
strongly supports the hypothesis that therapeutic approaches,
aimed at suppressing b-catenin activity, might be highly beneﬁ-
cial for the treatment of human liver cancer. On the other hand,
the authors found that b-catenin suppression could be an effec-
tive anti-tumour strategy exclusively in HCC subsets in which
the Wnt/b-catenin pathway plays a predominant role, while
being ineffective in b-catenin-negative tumours. These data are
in accordance with recent ﬁndings, showing that treatments with
the multikinase inhibitor sorafenib or the c-Met inhibitor tivanti-
nib are beneﬁcial primarily in HCC cases with speciﬁc molecular
signatures [18,19]. Furthermore, ﬁndings in the DEN/PB mouse
models might help to explain the unsatisfactory results of recent
clinical trials, such as the STORM and the EVOLVE-1 trial. The
STORM trial was designed to evaluate the efﬁcacy and safety of
sorafenib treatment vs. placebo in the adjuvant treatment of
HCC after potentially curative treatments (clinicalTrials.gov;
identiﬁer: NCT00692770), whereas the EVOLVE-1 trial was aimed
at evaluating the efﬁcacy of the rapamycin homolog everolimus
in HCC patients in which sorafenib was either ineffective or notβ-catenin+
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Fig. 1. Schematic representation of the protocol employed by Delgado et al. [15]. (A
hepatocarcinogen diethylnitrosamine, followed 3 weeks later by initiation of a diet c
harbouring b-catenin mutations (b-catenin+ liver tumours). Of note, liver tumour develop
blunted arrow) against b-catenin in these mice. (B) A second group of C3H/He male m
tumours harbouring Ha-Ras or B-Raf mutations (Ha-Ras+ or B-Raf+ liver tumours) but
administration of LNA against b-catenin.
258 Journal of Hepatology 201properly tolerated [20]. It is highly likely that the failure of these
therapeutic approaches resides, at least partly, in the inclusion of
HCC cases into the trial that did not harbour the ‘‘appropriate’’
molecular alterations.
Although the study by Delgado et al. has signiﬁcantly improved
our knowledge on the impact of b-catenin suppression in HCC
development, many important questions on this topic remain to
be addressed. For instance, while hepatocarcinogenesis in the
DEN/PB model is addicted to b-catenin signalling, human
b-catenin-positive HCCs are presumably characterized by hetero-
geneous molecular features, which might provide at least partial
resistance to the anti-tumour effect of b-catenin depletion via
compensatory activation of alternative oncogenic pathways. To
clarify the latter issue, the treatment with speciﬁc LNA against
b-catenin should be employed in mouse models in which activa-
tion of the b-catenin signalling is associated with other molecular
alterations frequently occurring in human HCC, such as activation
of the AKT or c-Met pathways or inactivation of the SPRY2 tumour
suppressor gene. Mouse models harbouring these molecular fea-
tures are already available [14], andmight be of high help to deter-
mine whether the presence of additional oncogenic alterations is
able to override the anti-neoplastic activity following b-catenin
suppression. Furthermore, these or similar mouse models might
be useful to evaluate the effectiveness of treatments in which
b-catenin inhibition is coupled to other therapeutic approaches.
Another crucial point that requires caution and must be fully
addressed before b-catenin inhibition is established as a thera-
peutic strategy against human liver cancer is the consequence
of b-catenin suppression in HCC patients in terms of potentially
fatal side effects. Indeed, as b-catenin is vital to adherens junc-
tions, its inhibition might be deleterious for patient survival.
However, both in vitro and in vivo studies have shown that
b-catenin loss is compensated by upregulation of c-catenin [6],
suggesting that suppression of b-catenin might be well tolerated
by patients.Anti-β-catenin
LNA
B
DEN
only
Ha-ras+ or B-raf+
liver tumors
No inhibition of liver tumor 
development
) Six-week old C3H/He male mice were injected intraperitoneally with the potent
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ment was completely suppressed by treatment with locked nucleic acid (LNA; red
ice was subjected to the administration of DEN only. These mice developed liver
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Finally, to optimize the effectiveness of anti-b-catenin tar-
geted therapies in human HCC, reliable biomarkers, able to pre-
dict the patient’s response to a given drug, should be identiﬁed.
In this regard, serum LECT2 has been recently envisioned has a
reliable biomarker of b-catenin signalling activity in mice but
not in humans [17]. Thus, additional studies, using large-scale
genomic and proteomic approaches are needed to identify rele-
vant biomarker(s) for effective targeted therapies in b-catenin-
positive tumours. As b-catenin targets are tissue-speciﬁc, such
large-scale studies will also be extremely helpful to discover
the crucial effectors of b-catenin in the liver.Conﬂict of interest
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